Helix Holdings LLC
CIK: 0001821548
Associated companies
Transaction History
| MLTX | ▼ Sell | Other | 2,785,000 | $0 | 4/5/2022 | View on chart |
| MLTX | ▼ Sell | Other | 2,785,000 | $0 | 4/5/2022 | View on chart |
We use analytics to understand how market-wall is used. No personal data is sold.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
MoonLake Immunotherapeutics presents case for sonelokimab approval
MoonLake Immunotherapeutics has presented its case for the approval of its drug sonelokimab, according to a report from RBC. The company highlighted data that could support regulatory review. This development may influence investor perception of the drug’s potential. The announcement comes as the share price remains below its 52‑week high.
MoonLake Immunotherapeutics presents case for sonelokimab approval. MoonLake Immunotherapeutics has presented its case for the approval of its drug sonelokimab, according to a report from RBC. The company highlighted data that could support regulatory review. This development may influence investor perception of the drug’s potential. The announcement comes as the share price remains below its 52‑week high.